These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20923604)

  • 1. Spinal muscular atrophy: from animal model to clinical trial.
    Zanoteli E; Maximino JR; Conti Reed U; Chadi G
    Funct Neurol; 2010; 25(2):73-9. PubMed ID: 20923604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.
    Wirth B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):87-95. PubMed ID: 12215230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is RNA manipulation a viable therapy for spinal muscular atrophy?
    Horne C; Young PJ
    J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal muscular atrophy: from gene to therapy.
    Wirth B; Brichta L; Hahnen E
    Semin Pediatr Neurol; 2006 Jun; 13(2):121-31. PubMed ID: 17027862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy.
    Watihayati MS; Fatemeh H; Marini M; Atif AB; Zahiruddin WM; Sasongko TH; Tang TH; Zabidi-Hussin ZA; Nishio H; Zilfalil BA
    Brain Dev; 2009 Jan; 31(1):42-5. PubMed ID: 18842367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy.
    Shababi M; Mattis VB; Lorson CL
    Drug News Perspect; 2010 Oct; 23(8):475-82. PubMed ID: 21031163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).
    Wirth B
    Hum Mutat; 2000; 15(3):228-37. PubMed ID: 10679938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
    El-Khodor BF; Edgar N; Chen A; Winberg ML; Joyce C; Brunner D; Suárez-Fariñas M; Heyes MP
    Exp Neurol; 2008 Jul; 212(1):29-43. PubMed ID: 18455159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantitative analysis of the genes determining spinal muscular atrophy].
    Nagymihály M; Herczegfalvi A; Tímár L; Karcagi V
    Ideggyogy Sz; 2009 Nov; 62(11-12):390-7. PubMed ID: 20025129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
    Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
    Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal muscular atrophy: newborn and carrier screening.
    Prior TW
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):23-36, Table of Contents. PubMed ID: 20494255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy.
    DiMatteo D; Callahan S; Kmiec EB
    Exp Cell Res; 2008 Feb; 314(4):878-86. PubMed ID: 18078930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy.
    Vezain M; Saugier-Veber P; Melki J; Toutain A; Bieth E; Husson M; Pedespan JM; Viollet L; Pénisson-Besnier I; Fehrenbach S; Bou J; Frébourg T; Tosi M
    Eur J Hum Genet; 2007 Oct; 15(10):1054-62. PubMed ID: 17609673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H; Buckley DM; Vale SM; Krogman M; Rose FF; Garcia ML; Lorson CL
    Neuromuscul Disord; 2012 Mar; 22(3):277-85. PubMed ID: 22079083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
    Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
    Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells.
    Boda B; Mas C; Giudicelli C; Nepote V; Guimiot F; Levacher B; Zvara A; Santha M; LeGall I; Simonneau M
    Eur J Hum Genet; 2004 Sep; 12(9):729-37. PubMed ID: 15162126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.
    Liu H; Shafey D; Moores JN; Kothary R
    J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.